CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma

Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in a small subset of patients with non-small-cell lung cancer (NSCLC). The ALK inhibitors are highly effective in NSCLC patients harboring ALK rearrangements; however, most patients acquire resistance to the therapy following...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: An, Rong, Wang, Yisong, Voeller, Donna, Gower, Arjan, Kim, In-Kyu, Zhang, Yu-Wen, Giaccone, Giuseppe
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2016
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5045389/
https://ncbi.nlm.nih.gov/pubmed/27078848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8638
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk